Tibolone histology of the endometrium and breast endpoints study

design of the trial and endometrial histology at baseline in postmenopausal women

David F. Archer, Susan Hendrix, Alex Ferenczy, Juan Felix, John Christopher G. Gallagher, Janice Rymer, Sven O. Skouby, Wil den Hollander, Victoria Stathopoulos, Frans A. Helmond

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To address the endometrial safety of tibolone. Design: The Tibolone Histology of the Endometrium and Breast Endpoints Study (THEBES) is a randomized, double-blind, parallel-group trial of tibolone compared with continuous combined conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA). Setting: Multi-country, multi-center ambulatory care setting. Patient(s): A total of 5,185 subjects were screened, and biopsies were obtained from 4,446 women. Intervention(s): Participants were randomized in a 1:1:2 ratio, to tibolone (1.25 or 2.5 mg/d) or CEE-MPA. Main Outcome Measure(s): The one-sided 95% confidence intervals for the incidence of hyperplasia or cancer were evaluated for tibolone compared with CEE-MPA. Result(s): Endometrial biopsy results at baseline: atrophic (87.29%), inactive (0.25%), proliferative (6.12%), secretory (2.86%), menstrual type (0.40%), and hyperplasia (0.18%). Only subjects with atrophic or inactive endometrium were eligible for this study, and 3% of the women at screening either had no tissue (0.18%) or had an amount of tissue that was insufficient for diagnosis (2.72%). Three thousand two hundred forty postmenopausal women with a mean (±SD) age of 54.4 ± 4.4 years and a mean time since menopause of 4.5 ± 3.6 years were randomized. Conclusion(s): The Tibolone Histology of the Endometrium and Breast Endpoints Study is a prospective, randomized clinical trial, designed to provide evidence of the endometrial safety of tibolone compared with estrogen and progestogen. Screening endometrial histology shows a low prevalence of endometrial hyperplasia (0.18%) and no carcinoma.

Original languageEnglish
Pages (from-to)866-878
Number of pages13
JournalFertility and Sterility
Volume88
Issue number4
DOIs
StatePublished - Oct 2007

Fingerprint

tibolone
Endometrium
Histology
Breast
Conjugated (USP) Estrogens
Medroxyprogesterone Acetate
Hyperplasia
Endometrial Hyperplasia
Biopsy
Safety
Progestins
Ambulatory Care
Menopause

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Tibolone histology of the endometrium and breast endpoints study : design of the trial and endometrial histology at baseline in postmenopausal women. / Archer, David F.; Hendrix, Susan; Ferenczy, Alex; Felix, Juan; Gallagher, John Christopher G.; Rymer, Janice; Skouby, Sven O.; den Hollander, Wil; Stathopoulos, Victoria; Helmond, Frans A.

In: Fertility and Sterility, Vol. 88, No. 4, 10.2007, p. 866-878.

Research output: Contribution to journalArticle

Archer, DF, Hendrix, S, Ferenczy, A, Felix, J, Gallagher, JCG, Rymer, J, Skouby, SO, den Hollander, W, Stathopoulos, V & Helmond, FA 2007, 'Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women', Fertility and Sterility, vol. 88, no. 4, pp. 866-878. https://doi.org/10.1016/j.fertnstert.2006.12.052
Archer, David F. ; Hendrix, Susan ; Ferenczy, Alex ; Felix, Juan ; Gallagher, John Christopher G. ; Rymer, Janice ; Skouby, Sven O. ; den Hollander, Wil ; Stathopoulos, Victoria ; Helmond, Frans A. / Tibolone histology of the endometrium and breast endpoints study : design of the trial and endometrial histology at baseline in postmenopausal women. In: Fertility and Sterility. 2007 ; Vol. 88, No. 4. pp. 866-878.
@article{397e4ee3f6d44d61aad94bce111c0880,
title = "Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women",
abstract = "Objective: To address the endometrial safety of tibolone. Design: The Tibolone Histology of the Endometrium and Breast Endpoints Study (THEBES) is a randomized, double-blind, parallel-group trial of tibolone compared with continuous combined conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA). Setting: Multi-country, multi-center ambulatory care setting. Patient(s): A total of 5,185 subjects were screened, and biopsies were obtained from 4,446 women. Intervention(s): Participants were randomized in a 1:1:2 ratio, to tibolone (1.25 or 2.5 mg/d) or CEE-MPA. Main Outcome Measure(s): The one-sided 95{\%} confidence intervals for the incidence of hyperplasia or cancer were evaluated for tibolone compared with CEE-MPA. Result(s): Endometrial biopsy results at baseline: atrophic (87.29{\%}), inactive (0.25{\%}), proliferative (6.12{\%}), secretory (2.86{\%}), menstrual type (0.40{\%}), and hyperplasia (0.18{\%}). Only subjects with atrophic or inactive endometrium were eligible for this study, and 3{\%} of the women at screening either had no tissue (0.18{\%}) or had an amount of tissue that was insufficient for diagnosis (2.72{\%}). Three thousand two hundred forty postmenopausal women with a mean (±SD) age of 54.4 ± 4.4 years and a mean time since menopause of 4.5 ± 3.6 years were randomized. Conclusion(s): The Tibolone Histology of the Endometrium and Breast Endpoints Study is a prospective, randomized clinical trial, designed to provide evidence of the endometrial safety of tibolone compared with estrogen and progestogen. Screening endometrial histology shows a low prevalence of endometrial hyperplasia (0.18{\%}) and no carcinoma.",
author = "Archer, {David F.} and Susan Hendrix and Alex Ferenczy and Juan Felix and Gallagher, {John Christopher G.} and Janice Rymer and Skouby, {Sven O.} and {den Hollander}, Wil and Victoria Stathopoulos and Helmond, {Frans A.}",
year = "2007",
month = "10",
doi = "10.1016/j.fertnstert.2006.12.052",
language = "English",
volume = "88",
pages = "866--878",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Tibolone histology of the endometrium and breast endpoints study

T2 - design of the trial and endometrial histology at baseline in postmenopausal women

AU - Archer, David F.

AU - Hendrix, Susan

AU - Ferenczy, Alex

AU - Felix, Juan

AU - Gallagher, John Christopher G.

AU - Rymer, Janice

AU - Skouby, Sven O.

AU - den Hollander, Wil

AU - Stathopoulos, Victoria

AU - Helmond, Frans A.

PY - 2007/10

Y1 - 2007/10

N2 - Objective: To address the endometrial safety of tibolone. Design: The Tibolone Histology of the Endometrium and Breast Endpoints Study (THEBES) is a randomized, double-blind, parallel-group trial of tibolone compared with continuous combined conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA). Setting: Multi-country, multi-center ambulatory care setting. Patient(s): A total of 5,185 subjects were screened, and biopsies were obtained from 4,446 women. Intervention(s): Participants were randomized in a 1:1:2 ratio, to tibolone (1.25 or 2.5 mg/d) or CEE-MPA. Main Outcome Measure(s): The one-sided 95% confidence intervals for the incidence of hyperplasia or cancer were evaluated for tibolone compared with CEE-MPA. Result(s): Endometrial biopsy results at baseline: atrophic (87.29%), inactive (0.25%), proliferative (6.12%), secretory (2.86%), menstrual type (0.40%), and hyperplasia (0.18%). Only subjects with atrophic or inactive endometrium were eligible for this study, and 3% of the women at screening either had no tissue (0.18%) or had an amount of tissue that was insufficient for diagnosis (2.72%). Three thousand two hundred forty postmenopausal women with a mean (±SD) age of 54.4 ± 4.4 years and a mean time since menopause of 4.5 ± 3.6 years were randomized. Conclusion(s): The Tibolone Histology of the Endometrium and Breast Endpoints Study is a prospective, randomized clinical trial, designed to provide evidence of the endometrial safety of tibolone compared with estrogen and progestogen. Screening endometrial histology shows a low prevalence of endometrial hyperplasia (0.18%) and no carcinoma.

AB - Objective: To address the endometrial safety of tibolone. Design: The Tibolone Histology of the Endometrium and Breast Endpoints Study (THEBES) is a randomized, double-blind, parallel-group trial of tibolone compared with continuous combined conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA). Setting: Multi-country, multi-center ambulatory care setting. Patient(s): A total of 5,185 subjects were screened, and biopsies were obtained from 4,446 women. Intervention(s): Participants were randomized in a 1:1:2 ratio, to tibolone (1.25 or 2.5 mg/d) or CEE-MPA. Main Outcome Measure(s): The one-sided 95% confidence intervals for the incidence of hyperplasia or cancer were evaluated for tibolone compared with CEE-MPA. Result(s): Endometrial biopsy results at baseline: atrophic (87.29%), inactive (0.25%), proliferative (6.12%), secretory (2.86%), menstrual type (0.40%), and hyperplasia (0.18%). Only subjects with atrophic or inactive endometrium were eligible for this study, and 3% of the women at screening either had no tissue (0.18%) or had an amount of tissue that was insufficient for diagnosis (2.72%). Three thousand two hundred forty postmenopausal women with a mean (±SD) age of 54.4 ± 4.4 years and a mean time since menopause of 4.5 ± 3.6 years were randomized. Conclusion(s): The Tibolone Histology of the Endometrium and Breast Endpoints Study is a prospective, randomized clinical trial, designed to provide evidence of the endometrial safety of tibolone compared with estrogen and progestogen. Screening endometrial histology shows a low prevalence of endometrial hyperplasia (0.18%) and no carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=34848917549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848917549&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2006.12.052

DO - 10.1016/j.fertnstert.2006.12.052

M3 - Article

VL - 88

SP - 866

EP - 878

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 4

ER -